Literature DB >> 1711511

Major acute-phase reactant synthesis during chronic inflammation in amyloid-susceptible and -resistant mouse strains.

K Zahedi1, W A Gonnerman, F C Debeer, M C Debeer, D M Steel, J D Sipe, A S Whitehead.   

Abstract

Hepatic levels of mRNA specific for total serum amyloid A (SAA), the SAA1 and SAA2 isotypes, serum amyloid P (SAP), C-reactive protein (CRP), and fibronectin, as well as the plasma concentrations of SAA and SAP were examined in amyloid-resistant (A/J) and amyloid-susceptible (CBA/J) mice during azocasein-induced chronic inflammation. In both strains hepatic SAA and SAP mRNA levels and plasma SAA and SAP protein concentrations increased dramatically during the early stages of inflammation; this was followed by a decrease to concentrations that were maintained at levels considerably higher than background. The ratios of SAA1 and SAA2 mRNA and plasma protein were 1:1 throughout. This indicated that there was no preferential accumulation of mRNA specifying a particular isotype and no preferential synthesis or clearance of a particular isotype during chronic inflammation and the early stages of amyloidogenesis in either strain. Similarly, hepatic SAP mRNA levels in both strains increased dramatically during the early stages of inflammation and were subsequently maintained at elevated levels. Plasma SAP concentrations increased rapidly during the first three days of the study in both A/J and CBA/J mice; however, during the later stages of inflammation, A/J plasma SAP levels decreased to a steady-state concentration that was approximately half that observed in CBA/J mice. Our results identify differences in the hepatic mRNA and plasma protein levels of the major mouse acute-phase reactants (APR) in the amyloid-resistant A/J and amyloid-susceptible CBA/J mouse strains. These findings are consistent with circulating inflammatory APR concentrations contributing, together with other factors, to the onset and pathogenesis of secondary amyloidosis.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1711511     DOI: 10.1007/bf00917905

Source DB:  PubMed          Journal:  Inflammation        ISSN: 0360-3997            Impact factor:   4.092


  29 in total

1.  Structure of the murine serum amyloid A gene family. Gene conversion.

Authors:  C A Lowell; D A Potter; R S Stearman; J F Morrow
Journal:  J Biol Chem       Date:  1986-06-25       Impact factor: 5.157

2.  Mouse C-reactive protein. Generation of cDNA clones, structural analysis, and induction of mRNA during inflammation.

Authors:  A S Whitehead; K Zahedi; M Rits; R F Mortensen; J M Lelias
Journal:  Biochem J       Date:  1990-02-15       Impact factor: 3.857

3.  Biochemical evidence for the biphasic development of experimental amyloidosis.

Authors:  J D Sipe; K P McAdam; F Uchino
Journal:  Lab Invest       Date:  1978-01       Impact factor: 5.662

4.  Experimental amyloidosis. Role of antigenicity and rapid induction.

Authors:  D T Janigan; R L Druet
Journal:  Am J Pathol       Date:  1966-06       Impact factor: 4.307

5.  Acute phase induction of mouse serum amyloid P component. Correlation with other parameters of inflammation.

Authors:  K Zahedi; A S Whitehead
Journal:  J Immunol       Date:  1989-11-01       Impact factor: 5.422

6.  Molecular genetics of mouse serum amyloid P component (SAP): cloning and gene mapping.

Authors:  A S Whitehead; M Rits; J Michaelson
Journal:  Immunogenetics       Date:  1988       Impact factor: 2.846

7.  Circulating serum amyloid P component is the precursor of amyloid P component in tissue amyloid deposits.

Authors:  M L Baltz; D Caspi; D J Evans; I F Rowe; C R Hind; M B Pepys
Journal:  Clin Exp Immunol       Date:  1986-12       Impact factor: 4.330

8.  Diverse gene expression for isotypes of murine serum amyloid A protein during acute phase reaction.

Authors:  K Yamamoto; M Shiroo; S Migita
Journal:  Science       Date:  1986-04-11       Impact factor: 47.728

9.  Purification of mouse immunoglobulin heavy-chain messenger RNAs from total myeloma tumor RNA.

Authors:  C Auffray; F Rougeon
Journal:  Eur J Biochem       Date:  1980-06

10.  Fibronectin and C4-binding protein are selectively bound by aggregated amyloid P component.

Authors:  F C de Beer; M L Baltz; S Holford; A Feinstein; M B Pepys
Journal:  J Exp Med       Date:  1981-10-01       Impact factor: 14.307

View more
  6 in total

1.  Characterization of Bglu3, a mouse fasting glucose locus, and identification of Apcs as an underlying candidate gene.

Authors:  Jing Li; Zongji Lu; Qian Wang; Zhiguang Su; Yongde Bao; Weibin Shi
Journal:  Physiol Genomics       Date:  2012-01-24       Impact factor: 3.107

2.  Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures.

Authors:  B J Van Lenten; S Y Hama; F C de Beer; D M Stafforini; T M McIntyre; S M Prescott; B N La Du; A M Fogelman; M Navab
Journal:  J Clin Invest       Date:  1995-12       Impact factor: 14.808

Review 3.  Regulation of serum amyloid A protein expression during the acute-phase response.

Authors:  L E Jensen; A S Whitehead
Journal:  Biochem J       Date:  1998-09-15       Impact factor: 3.857

4.  Structural mechanism of serum amyloid A-mediated inflammatory amyloidosis.

Authors:  Jinghua Lu; Yadong Yu; Iowis Zhu; Yifan Cheng; Peter D Sun
Journal:  Proc Natl Acad Sci U S A       Date:  2014-03-24       Impact factor: 11.205

5.  Genetic control of inflammatory gene induction and NF-kappa B-like transcription factor activation in response to an atherogenic diet in mice.

Authors:  F Liao; A Andalibi; F C deBeer; A M Fogelman; A J Lusis
Journal:  J Clin Invest       Date:  1993-06       Impact factor: 14.808

6.  SAA fibrils involved in AA amyloidosis are similar in bulk and by single particle reconstitution: A MAS solid-state NMR study.

Authors:  Arpita Sundaria; Falk Liberta; Dilan Savran; Riddhiman Sarkar; Natalia Rodina; Carsten Peters; Nadine Schwierz; Christian Haupt; Matthias Schmidt; Bernd Reif
Journal:  J Struct Biol X       Date:  2022-07-19
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.